Skip to main content Accessibility help
×
Home
  • Print publication year: 2014
  • Online publication date: December 2014

3 - Clinical aspects of movement disorders

References

1. S. Fahn. Classification of movement disorders. Movement Disorders: Official Journal of the Movement Disorder Society 2011; 26: 947–57.
2. G. Fenelon, G. Percheron. Revision of the international classification of diseases. Movement Disorders: Official Journal of the Movement Disorder Society 1997; 12: 256–7.
3. W. F. Abdo, B. P. van de Warrenburg, D. J. Burn, N. P. Quinn, B. R. Bloem. The clinical approach to movement disorders. Nature Reviews Neurology 2010; 6: 29–37.
4. C. Ghez, J. Gordon. An introduction into movement. In: E. R. Kandel, J. H. Schwartz, T. M. Jessel (eds). Essentials of Neural Science and Behavior. Norwalk, Conneticut: Appleton and Lange. 1995: 489–500.
5. I. M. Donaldson, C. D. Marsden, S. A. Schneider, K. P. Bhatia. Marsden’s Book of Movement Disorders. Structure and Function of the Basal Ganglia. New York: Oxford University Press. 2012.
6. J. W. Mink. Basal ganglia. In: M. J. Zigmond, F. E. Bloom, S. C. Landis, J. L. Roberts, L. R. Squire (eds). Fundamental Neuroscience. San Diegeo: Academic Press. 1999: 951–72.
7. G. E. Alexander, M. R. DeLong, P. L. Strick. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annual Review of Neuroscience 1986; 9: 357–81.
8. R. L. Albin, A. B. Young, J. B. Penney. The functional anatomy of basal ganglia disorders. Trends in Neurosciences 1989; 12: 366–75.
9. M. R. DeLong. Primate models of movement disorders of basal ganglia origin. Trends in Neurosciences 1990; 13: 281–5.
10. A. Morel, M. Magnin, D. Jeanmonod. Multiarchitectonic and stereotactic atlas of the human thalamus. Journal of Comparative Neurology 1997; 387: 588–630.
11. M. N. Gallay, D. Jeanmonod, J. Liu, A. Morel. Human pallidothalamic and cerebellothalamic tracts: anatomical basis for functional stereotactic neurosurgery. Brain Structure & Function 2008; 212: 443–63.
12. E. E. Benarroch. Pedunculopontine nucleus: functional organization and clinical implications. Neurology 2013; 80: 1148–55.
13. R. Hassler. Zur Normalanatomie der Substantia nigra. Versuch einer architektonischen Gliederung. Journal für Psychologie und Neurologie 1937; 48: 1–55.
14. J. Olszewski, D. Baxter. Cytocharchitecture of the Human Brain Stem. Basel: Karger. 1954.
15. W. R. Gibb. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson’s disease. Brain Research 1992; 581: 283–91.
16. E. Lynd-Balta, S. N. Haber. The organization of midbrain projections to the striatum in the primate: sensorimotor-related striatum versus ventral striatum. Neuroscience 1994; 59: 625–40.
17. P. Damier, E. C. Hirsch, Y. Agid, A. M. Graybiel. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain: a Journal of Neurology 1999; 122: 1421–36.
18. C. R. Gerfen, T. M. Engber, L. C. Mahan, et al. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 1990; 250: 1429–32.
19. A. Nambu. A new dynamic model of the cortico-basal ganglia loop. Progress in Brain Research 2004; 143: 461–6.
20. J. A. Obeso, C. Marin, C. Rodriguez-Oroz, et al. The basal ganglia in Parkinson’s disease: current concepts and unexplained observations. Annals of Neurology 2008; 64 (Suppl. 2): S30–46.
21. P. Redgrave, M. Rodriguez, Y. Smith, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson’s disease. Nature Reviews Neuroscience 2010; 11: 760–72.
22. C. Hammond, H. Bergman, P. Brown. Pathological synchronization in Parkinson’s disease: networks, models and treatments. Trends in Neurosciences 2007; 30: 357–64.
23. C. R. Gerfen. The neostriatal mosaic: multiple levels of compartmental organization. Trends in Neurosciences 1992; 15: 133–9.
24. J. R. Crittenden, A. M. Graybiel. Basal ganglia disorders associated with imbalances in the striatal striosome and matrix compartments. Frontiers in Neuroanatomy 2011; 5: 59.
25. A. J. Bastian, E. Mugnaini, W. T. Thach. Cerebellum. In: M. J. Zigmond, F. E. Bloom, S. C. Landis, J. L. Roberts, L. R. Squire (eds). Fundamental Neuroscience. San Diego: Academic Press. 1999: 973–92.
26. J. Raethjen, G. Deuschl. The oscillating central network of essential tremor. Clinical Neurophysiology: Official Journal of the International Federation of Clinical Neurophysiology 2012; 123: 61–4.
27. J. Jankovic. Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery, and Psychiatry 2008; 79: 368–76.
28. W. R. Gibb, A. J. Lees. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry 1988; 51: 745–52.
29. W. Pirker. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Movement Disorders: Official Journal of the Movement Disorder Society 2003; 18 (Suppl. 7): S43–51.
30. B. R. Bloem, J. M. Hausdorff, J. E. Visser, N. Giladi. Falls and freezing of gait in Parkinson’s disease: a review of two interconnected, episodic phenomena. Movement Disorders: Official Journal of the Movement Disorder Society 2004; 19: 871–84.
31. G. Deuschl, P. Bain, M. Brin. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Movement Disorders: Official Journal of the Movement Disorder Society 1998; 13 (Suppl. 3): 2–23.
32. R. C. Helmich, M. Hallett, G. Deuschl, I. Toni, B. R. Bloem. Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits? Brain: a Journal of Neurology 2012; 135: 3206–26.
33. A. Albanese, K. Bhatia, S. B. Bressman, et al. Phenomenology and classification of dystonia: a consensus update. Movement Disorders: Official Journal of the Movement Disorder Society 2013; 28: 863–73.
34. S. G. Massaquoi, M. Hallett. Ataxia and other cerebellar syndromes. In: J. J. Jankovic, E. Tolosa (eds). Parkinson’s Disease and Movment Disorders, 4th edn. Philadelphia: Lippincott, Williams and Wilkins. 2002: 393–408.
35. F. Cardoso, K. Seppi, K. J. Mair, G. K. Wenning, W. Poewe. Seminar on choreas. Lancet Neurology 2006; 5: 589–602.
36. S. Gilman, G. K. Wenning, P. A. Low, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670–6.
37. H. Houlden, A. B. Singleton. The genetics and neuropathology of Parkinson’s disease. Acta Neuropathol 2012; 124: 325–38.
38. M. Stamelou, N. P. Quinn, K. P. Bhatia. “Atypical” atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide. Movement Disorders: Official Journal of the Movement Disorder Society 2013; 28: 1184–99.
39. K. P. Bhatia, C. D. Marsden. The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain: a Journal of Neurology 1994; 117: 859–76.
40. M. C. de Rijk, C. Tzourio, M. M. Breteler, et al. Prevalence of parkinsonism and Parkinson’s disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson’s disease. Journal of Neurology, Neurosurgery, and Psychiatry 1997; 62: 10–5.
41. K. R. Kumar, K. Lohmann, C. Klein. Genetics of Parkinson disease and other movement disorders. Current Opinion in Neurology 2012; 25: 466–74.
42. S. Y. Lim, A. E. Lang. The nonmotor symptoms of Parkinson’s disease–an overview. Movement disorders: official journal of the Movement Disorder Society 2010; 25 (Suppl. 1): S123–30.
43. H. Braak, K. Del Tredici, U. Rub, R. A. de Vos, E. N. Jansen Steur, E. Braak. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003; 24: 197–211.
44. D. J. Gelb, E. Oliver, S. Gilman. Diagnostic criteria for Parkinson disease. Archives of Neurology 1999; 56: 33–9.
45. I. Litvan, K. P. Bhatia, D. J. Burn, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Movement Disorders: Official Journal of the Movement Disorder Society 2003; 18: 467–86.
46. T. Witjas, E. Kaphan, J. P. Azulay, et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology 2002; 59: 408–13.
47. J. A. Obeso, M. C. Rodriguez-Oroz, P. Chana, et al. The evolution and origin of motor complications in Parkinson’s disease. Neurology 2000; 55: S13–20; discussion S1–3.
48. A. H. Evans, A. P. Strafella, D. Weintraub, M. Stacy. Impulsive and compulsive behaviors in Parkinson’s disease. Movement Disorders: Official Journal of the Movement Disorder Society 2009; 24: 1561–70.
49. B. Ravina, K. Marder, H. H. Fernandez, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Movement Disorders: Official Journal of the Movement Disorder Society 2007; 22: 1061–8.
50. A. J. Harding, G. A. Broe, G. M. Halliday. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain: a Journal of Neurology 2002; 125: 391–403.
51. J. Jankovic. Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Movement Disorders: Official Journal of the Movement Disorder Society 2010; 25: 527–8.
52. M. Emre, D. Aarsland, R. Brown, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Movement Disorders: Official Journal of the Movement Disorder Society 2007; 22: 1689–707.
53. M. A. Hely, W. G. Reid, M. A. Adena, G. M. Halliday, J. G. Morris. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Movement Disorders: Official Journal of the Movement Disorder Society 2008; 23: 837–44.
54. R. Savica, B. R. Grossardt, J. H. Bower, J. E. Ahlskog, W. A. Rocca. Incidence and pathology of synucleinopathies and tauopathies related to parkinsonism. JAMA Neurology 2013; 70: 859–66.
55. G. K. Wenning, F. Krismer. Multiple system atrophy. Handbook of Clinical Neurology 2013; 117: 229–41.
56. M.-S. A. R. Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. New England Journal of Medicine 2013; 369: 233–44.
57. K. Seppi, W. Poewe. Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clinics of North America 2010; 20: 29–55.
58. D. Berg, J. D. Steinberger, C. Warren Olanow, T. P. Naidich, T. A. Yousry. Milestones in magnetic resonance imaging and transcranial sonography of movement disorders. Movement Disorders: Official Journal of the Movement Disorder Society 2011; 26: 979–92.
59. M. Savoiardo, M. Grisoli. Magnetic resonance imaging of movement disorders. In: J. Jankovic, E. Tolosa (eds). Parkinson’s Disease and Movement Disorders, 4th edn. Philadelphia: Lippincott, Williams and Wilkins. 2002: 596–609.
60. M. Warmuth-Metz, M. Naumann, I. Csoti, L. Solymosi. Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy. Archives of Neurology 2001; 58: 1076–9.
61. S. E. Lee, G. D. Rabinovici, M. C. Mayo, et al. Clinicopathological correlations in corticobasal degeneration. Annals of Neurology 2011; 70: 327–40.
62. H. N. van Wassenaer-van Hall, A. G. van den Heuvel, A. Algra, T. U. Hoogenraad, W. P. Mali. Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology 1996; 198: 531–6.
63. A. McNeill, D. Birchall, S. J. Hayflick, et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology 2008; 70: 1614–9.
64. D. J. Brooks, V. Ibanez, G. V. Sawle, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Annals of Neurology 1990; 28: 547–55.
65. A. J. Stoessl. Neuroimaging in Parkinson’s disease. Neurotherapeutics: Journal of the American Society for Experimental NeuroTherapeutics 2011; 8: 72–81.
66. T. Brucke, S. Asenbaum, W. Pirker, et al. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. Journal of Neural Transmission Supplementum 1997; 50: 9–24.
67. J. M. Fearnley, A. J. Lees. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain: a Journal of Neurology 1991; 114: 2283–301.
68. J. P. Seibyl, K. L. Marek, D. Quinlan, et al. Decreased single-photon emission computed tomographic [123I]β-CIT striatal uptake correlates with symptom severity in Parkinson’s disease. Annals of Neurology 1995; 38: 589–98.
69. H. T. Benamer, J. Patterson, D. J. Wyper, et al. Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Movement Disorders: Official Journal of the Movement Disorder Society 2000; 15: 692–8.
70. C. H. van Dyck, J. P. Seibyl, R. T. Malison, et al. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CITSPECT. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 1995; 36: 1175–81.
71. S. Asenbaum, W. Pirker, P. Angelberger, et al. [123I]β-CIT and SPECT in essential tremor and Parkinson’s disease. Journal of Neural Transmission 1998; 105: 1213–28.
72. H. W. Shin, S. J. Chung. Drug-induced parkinsonism. Journal of Clinical Neurology 2012; 8: 15–21.
73. A. C. Felicio, C. Godeiro-Junior, T. S. Moriyama, et al. Degenerative parkinsonism in patients with psychogenic parkinsonism: a dopamine transporter imaging study. Clinical Neurology and Neurosurgery 2010; 112: 282–5.
74. W. Gerschlager, G. Bencsits, W. Pirker, et al. [123I]β-CIT SPECT distinguishes vascular parkinsonism from Parkinson’s disease. Movement Disorders: Official Journal of the Movement Disorder Society 2002; 17: 518–23.
75. J. Zijlmans, A. Evans, F. Fontes, et al. [123I] FP-CIT spect study in vascular parkinsonism and Parkinson’s disease. Movement Disorders: Official Journal of the Movement Disorder Society 2007; 22: 1278–85.
76. L. D. Perju-Dumbrava, G. G. Kovacs, S. Pirker, et al. Dopamine transporter imaging in autopsy-confirmed Parkinson’s disease and multiple system atrophy. Movement Disorders: Official Journal of the Movement Disorder Society 2012; 27: 65–71.
77. Z. Walker, D. C. Costa, R. W. Walker, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. Journal of Neurology, Neurosurgery, and Psychiatry 2002; 73: 134–40.
78. S. J. Colloby, S. McParland, J. T. O’Brien, J. Attems. Neuropathological correlates of dopaminergic imaging in Alzheimer’s disease and Lewy body dementias. Brain: a Journal of Neurology 2012; 135: 2798–808.
79. T. Brucke, S. Wenger, S. Asenbaum, et al. Dopamine D2 receptor imaging and measurement with SPECT. Advances in Neurology 1993; 60: 494–500.
80. S. Braune, M. Reinhardt, R. Schnitzer, A. Riedel, C. H. Lucking. Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 1999; 53: 1020–5.
81. S. Hellwig, F. Amtage, A. Kreft, et al. [18F]FDG-PET is superior to [123I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012; 79: 1314–22.
82. L. K. Teune, A. L. Bartels, B. M. de Jong, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Movement Disorders: Official Journal of the Movement Disorder Society 2010; 25: 2395–404.
83. D. J. Brooks, N. Pavese. Imaging biomarkers in Parkinson’s disease. Progress in Neurobiology 2011; 95: 614–28.